

Reference:	FOI.9395.22
Subject:	Diffuse Large B Cell Lymphoma (DLBCL)
Date of Request:	14 July 2022

Requested:

1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?
2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?
3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
 - R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - Other immuno-chemotherapy
 - Other chemotherapy
 - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
 - Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment
 - Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only
 - Tisagenlecleucel
 - Axicabtagene ciloleucel
 - Lisocabtagene maraleucel
4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:
 - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
 - CAR-T therapy (Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene maraleucel)
5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare Team, which holds a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients' medical records, to establish the type of cancer diagnosed and therapies used to treat the patients. It is estimated that

conducting this search would take longer than the 18 hours 'appropriate limit' as stated within the Freedom of Information Act 2000 (FoIA).

The UHB is therefore applying an exemption under Section 12 of the FoIA, which provides an exemption from a public authority's obligation to comply with a request for information, where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. We therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB, who may be able to help you with your enquiry. The contact details are as follows:-

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.